CompanyBioInvent International AB
Sweden
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The companyâs strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives.
Private/Public:
public
Phone:+46 (0)46-286 85 50
Fax:+46 (0)46-211 08 06
Email:[email protected]
Website:http://www.bioinvent.com/
Address:Ideon Science Park SE-223 70 Lund, Sweden
1996
Since
1
Country
8
Top Service Categories
80
Sub-Service Categories
Top Services
Product Groups
For Services/Products
Analytical
Analytical lab services
Discovery and Preclinical
Specific Services-Discovery
API/Biologicals Production
API/Biologics development and manufacturing
- API development phases/scales
- API process capabilities
- API process equipment
- API reactions
- Biologics development and manufacturing
Formulation
Formulation development related
Formulation types
Package and Label
Specific Services - Packaging etc.
Bioanalytical
Bioanalytical assays
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Corporate Headquarters | Ideon Science Park SE-223 70 Lund | +46 (0)46-286 85 50 | Lund | +46 (0)46-211 08 06 | Sweden |
- (12.Apr.2021) BioInvent's Partner Oncurious NV Presents Phase I Data on TB-403 in Pediatric Cancer
- (07.Apr.2021) BioInvent Receives IND Approval for Phase I/IIa Trial of Anti-TNFR2 Antibody BI-1808
- (31.Mar.2021) Change in the Number of Shares and Votes in BioInvent International AB
- (31.Mar.2021) Change in the Number of Shares and Votes in BioInvent International AB
- (23.Mar.2021) Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021
- (11.Mar.2021) BioInvent Presents Proof-Of-Concept Data on Anti-FcyRIIB Antibody BI-1607 at AACR Annual Meeting 2021
- (01.Mar.2021) BioInvent and Transgene Has Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
- (26.Feb.2021) Change in the Number of Shares and Votes in BioInvent International AB
- (23.Feb.2021) BioInvent International Financial Statement January 1 - December 31, 2020
- (23.Feb.2021) BioInvent Successfully Carries out a Directed Share Issue of Approximately SEK 962 Million (Approximately USD 116 Million)
- (28.Jan.2021) BioInvent Phase I/IIa Data Suggest BI-1206 Restores Activity of Rituximab in Relapsed Non-Hodgkin's Lymphoma Patients
- (26.Jan.2021) BioInvent Has Enrolled First Patient in a Phase I/IIa Trial of the First-In-Class Anti-Tnfr2 Antibody BI-1808 for the Treatment of Patients With Solid Tumors and CTCL
- (19.Jan.2021) Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-Ctla4-Armed Oncolytic Virus BT-001 in Solid Tumors
- (11.Jan.2021) BioInvent Streamlines Agreement on Anti-FcγRllB Antibody, BI-1206, Ahead of Phase I/II Data
- (22.Dec.2020) BioInvent Receives $3 Million Payment Related to Selection of Antibodies Under Collaboration With Pfizer Inc
- (21.Dec.2020) Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors
- (07.Dec.2020) Record Date for Reverse Share Split in BioInvent International Determined
- (27.Nov.2020) Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020
- (26.Nov.2020) BioInvent and Cantargia Sign Manufacturing Agreement for Monoclonal Antibody CAN10
- (09.Nov.2020) BioInvent and Transgene Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting
- (09.Nov.2020) BioInvent Presents New Preclinical Data on BI-1808, a First-In-Class Anti-Tnfr2 Antibody at the SITC 35th Anniversary Annual Meeting
- (04.Nov.2020) BioInvent Presents Promising New Clinical and Preclinical Data on Anti-FcγRllB Antibody, BI-1206, at the ASH Annual Meeting
- (29.Oct.2020) BioInvent Interim Report January 1 - September 30, 2020
- (27.Oct.2020) BioInvent Licenses Anti-FcγRllB Antibody BI-1206 to CASI Pharmaceuticals for Greater China Region
- (27.Oct.2020) Notice to Extraordinary General Meeting in BioInvent International AB
- (26.Oct.2020) CTA Approval of BioInvent's BI-1808, a First-In-Class Anti-TNFR2 Antibody, Sets Stage for Phase I/IIa Trial
- (22.Oct.2020) BioInvent Receives €2 Million Milestone From Daiichi Sankyo
- (31.Aug.2020) Change in the number of shares and votes in BioInvent International AB
- (27.Aug.2020) BioInvent Interim Report January 1 - June 30, 2020
- (05.Aug.2020) BioInvent's Repair Rights Issue of Approximately SEK 139 Million Was Heavily Oversubscribed
- (31.Jul.2020) Change in the Number of Shares and Votes in BioInvent International AB
- (22.Jul.2020) BioInvent's BI-1206 Could Improve Treatment in Several Cancers
- (17.Jul.2020) BioInvent International Publ : Publishes Prospectus Relating to the Rights Issue
- (01.Jul.2020) BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc
- (30.Jun.2020) Change in the Number of Shares and Votes in BioInvent International AB
- (30.Jun.2020) BioInvent Submits a CTA for a Phase I/IIa Trial of BI-1808, a First-In-Class Anti-TNFR2 Antibody for the Treatment of Patients with Solid Tumors and CTCL
- (23.Jun.2020) BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA for the Treatment of Patients With Solid Tumors
- (22.Jun.2020) BioInvent Presents Proof-Of-Concept Data for Two TNFR2-targeting Antibodies
- (22.Jun.2020) BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
- (09.Jun.2020) BioInvent International Publ : Successfully Completes a Directed Share Issue of Approximately SEK 487 Million (Approximately EUR 47 Million)
- (28.May.2020) Resolutions at BioInvent's Annual General Meeting 2020
- (15.May.2020) BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors
- (15.May.2020) BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Deveplopment
- (30.Apr.2020) BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company
- (28.Apr.2020) BioInvent Interim Report January 1 - March 31, 2020
Analytical Equipment
Manufacturing Equipment
Facility Inspection/License Status
| Process | Capacity Low | Capacity High | Unit |
|---|---|---|---|
| API-fermentation | 40 | 1,000 | L/batch |